Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.
Analyst Upgrades and Downgrades
Separately, Barclays upped their price objective on Apollo Medical from $50.00 to $57.00 and gave the stock an "equal weight" rating in a research note on Monday, August 8th.
Apollo Medical Price Performance
Shares of NASDAQ:AMEH traded down $1.00 during midday trading on Thursday, reaching $46.64. 1,768 shares of the company were exchanged, compared to its average volume of 255,863. The stock has a market cap of $2.63 billion, a PE ratio of 29.78 and a beta of 0.69. The business's fifty day moving average is $45.04 and its two-hundred day moving average is $44.07. Apollo Medical has a one year low of $29.52 and a one year high of $133.23. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.41.
Insiders Place Their Bets
In other news, Director Linda Marsh sold 250,000 shares of the firm's stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $37.00, for a total transaction of $9,250,000.00. Following the completion of the transaction, the director now owns 270,081 shares in the company, valued at $9,992,997. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 11.51% of the company's stock.